Lupeng Pharmaceutical is a clinical-stage company dedicated to the discovery and development of innovative medicines for the treatment of hematological malignancies and autoimmune diseases. In pursuit of cutting-edge science, we are mainly focusing on clinically validated targets such as BTK, Bcl-2 and Bcl-xL and promoting international and domestic multi-center clinical development and commercialization.

Our investigational drugs Rocbrutinib(LP-168, BTKi), Lacutoclax (LP-108, Bcl-2i) and Nexatoclax (LP-118, Bcl-2/xL) have demonstrated promising efficacy with a favorable safety profile, positioning them as potential Best-in-Class (BIC) medicines. Specifically, Rocbrutinib and Lacutoclax have been granted regulatory approval by the National Medical Products Administration (NMPA) in China for pivotal registration trials.